-
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pre...
Abstract Background Ipilimumab is an approved immunotherapy that has shown an overall survival benefit in patients with cutaneous metastatic melanoma in two phase III trials. As...
